Nuclea Biotechnologies Raises $1.1M Toward $2.5M Financing Round | GenomeWeb

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies has raised $1.1 million toward a targeted $2.5 million financing round.

The company disclosed the raise in a document filed with the US Securities and Exchange Commission this week. A spokesman told GenomeWeb Daily News that the Pittsfield, Mass.-based firm plans to close the $2.5 million round at the end of next month. He said that Nuclea would not be disclosing who the investors are or how the funds from the financing would be used until then.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.